Canada markets open in 6 hours 44 minutes

Glaukos Corporation (GKOS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
100.93-0.17 (-0.17%)
At close: 04:00PM EDT
100.93 0.00 (0.00%)
After hours: 05:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close101.10
Open101.24
Bid66.00 x 900
Ask0.00 x 800
Day's Range100.75 - 103.66
52 Week Range45.38 - 103.66
Volume500,027
Avg. Volume508,683
Market Cap5.066B
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-2.78
Earnings DateMay 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est106.55
  • Business Wire

    Glaukos Announces the Release of its 2023 Sustainability Report

    ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.

  • Zacks

    Here's Why You Should Retain Glaukos (GKOS) Stock for Now

    Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

  • Zacks

    Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

    Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.